Vaccitech plc (VACC): Price and Financial Metrics

Vaccitech plc (VACC): $2.31

-0.12 (-4.94%)

POWR Rating

Component Grades








Add VACC to Watchlist
Sign Up

Industry: Biotech




#54 of 505

in industry

VACC Price/Volume Stats

Current price $2.31 52-week high $7.45
Prev. close $2.43 52-week low $2.02
Day low $2.31 Volume 7,481
Day high $2.47 Avg. volume 50,256
50-day MA $2.38 Dividend yield N/A
200-day MA $2.81 Market Cap 88.59M

VACC Stock Price Chart Interactive Chart >

VACC Stock Summary

  • VACC's went public 2.07 years ago, making it older than merely 6.82% of listed US stocks we're tracking.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for VACCITECH PLC; that's greater than it is for merely 10.03% of US stocks.
  • As for revenue growth, note that VACC's revenue has grown 100.07% over the past 12 months; that beats the revenue growth of 93.76% of US companies in our set.
  • Stocks that are quantitatively similar to VACC, based on their financial statements, market capitalization, and price volatility, are ONCT, ENTA, AEVA, ALGS, and RCUS.
  • VACC's SEC filings can be seen here. And to visit VACCITECH PLC's official web site, go to

VACC Valuation Summary

  • VACC's price/earnings ratio is -6.2; this is 125.73% lower than that of the median Healthcare stock.
  • Over the past 25 months, VACC's price/earnings ratio has gone up 20.9.

Below are key valuation metrics over time for VACC.

Stock Date P/S P/B P/E EV/EBIT
VACC 2023-05-23 3.2 0.4 -6.2 4.3
VACC 2023-05-22 3.2 0.4 -6.2 4.3
VACC 2023-05-19 3.1 0.4 -6.1 4.4
VACC 2023-05-18 3.1 0.4 -6.1 4.4
VACC 2023-05-17 3.0 0.4 -5.9 4.6
VACC 2023-05-16 3.0 0.4 -5.9 4.6

Vaccitech plc (VACC) Company Bio

Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

VACC Latest News Stream

Event/Time News Detail
Loading, please wait...

VACC Latest Social Stream

Loading social stream, please wait...

View Full VACC Social Stream

Latest VACC News From Around the Web

Below are the latest news stories about VACCITECH PLC that investors may wish to consider to help them evaluate VACC as an investment opportunity.

Newsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of Vaccitech plc ( NASDAQ:VACC ) shareholders today, when the analysts downgraded...

Yahoo | May 19, 2023

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress. “2023 has kicked off strongly for Vaccitech. In the first quarter, we s

Yahoo | May 12, 2023

Revenues Working Against Vaccitech plc's (NASDAQ:VACC) Share Price

Vaccitech plc's ( NASDAQ:VACC ) price-to-sales (or "P/S") ratio of 2x might make it look like a strong buy right now...

Yahoo | May 5, 2023

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human papillomavirus-related cervical lesionsInterim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 antigens OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on

Yahoo | April 17, 2023

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own.

Josh Enomoto on InvestorPlace | April 5, 2023

Read More 'VACC' Stories Here

VACC Price Returns

1-mo -2.94%
3-mo -23.00%
6-mo -1.49%
1-year -48.67%
3-year N/A
5-year N/A
YTD -1.70%
2022 -78.85%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!